Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).Read More
Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum-resistant ovarian cancer because of a clear efficacy signal.Read More
Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19.Read More
Maxim Group initiated coverage of Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and 12-month price target of $2. The stock was quoted at 42 cents at midday on Jan. 27Read More
The U.S. Patent and Trademark Office has issued a patent to Mateon Therapeutics (NASDAQ:MATN) and Baylor University that covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and methods of using these compounds for the treatment of conditions in which their regulation may be therapeutically useful.
In a statement, Dr. William Schwieterman, president and CEO of Mateon, said that for the past few years, the company has been working with Baylor University to pursue discovery and development of novel, small-molecule therapeutics that may be effective in oncology indications, and “we are continuing several interesting, early-stage opportunities in this field.”Read More
US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer.
In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US Oncology Research is selective about the studies it participates in. “So we are pleased they recognize the importance of developing CA4P for women with platinum-resistant ovarian cancer,” he added.Read More